Infinity Pharmaceuticals Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Infinity Pharmaceuticals saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 5,450,000 shares, a decline of 40.3% from the July 29th total of 9,130,000 shares. Based on an average daily volume of 7,180,000 shares, the short-interest ratio is presently 0.8 days. Approximately 6.3% of the company's stock are sold short.
View Infinity Pharmaceuticals' Short Interest.

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Infinity Pharmaceuticals.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced its earnings results on Tuesday, July, 27th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.01. The biotechnology company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.39 million. Infinity Pharmaceuticals had a negative net margin of 2,251.75% and a negative trailing twelve-month return on equity of 304.81%.
View Infinity Pharmaceuticals' earnings history.

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INFI stock has increased by 257.4% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19.

8 equities research analysts have issued twelve-month price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $9.63 in the next year. This suggests a possible upside of 166.6% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of INFI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.81%), Vanguard Group Inc. (4.94%), Millennium Management LLC (3.44%), Geode Capital Management LLC (1.59%), State Street Corp (1.57%) and Northern Trust Corp (1.11%).
View institutional ownership trends for Infinity Pharmaceuticals.

INFI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Renaissance Technologies LLC, Millennium Management LLC, Cubist Systematic Strategies LLC, Susquehanna International Group LLP, Jump Financial LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Infinity Pharmaceuticals or view top insider-selling stocks.

INFI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, GSA Capital Partners LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Infinity Pharmaceuticals or or view top insider-buying stocks.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFI stock can currently be purchased for approximately $3.61.

Infinity Pharmaceuticals has a market capitalization of $320.28 million and generates $1.72 million in revenue each year. The biotechnology company earns $-40,490,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

Infinity Pharmaceuticals employs 23 workers across the globe.

Infinity Pharmaceuticals was founded in 2000.

The official website for Infinity Pharmaceuticals is www.infi.com.

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at (617) 453-1000 or via email at [email protected].